Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 6/20 | 0.58 |
| ▸ | HDAC11 | Q96DB2 | 4/20 | 0.58 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.58 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.58 |
| ▸ | MAPT | P10636 | 4/20 | 0.57 |
| ▸ | POLB | P06746 | 4/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | MELK | Q14680 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7745473 | 0.91 | HDAC1 (0.61) | HDAC1HDAC11HDAC8HDAC6MAPT | |
| SCHEMBL16667740 | 0.87 | POLB (0.71) | HDAC1HDAC11HDAC8HDAC6MAPT | |
| SCHEMBL7746061 | 0.86 | HDAC1 (0.53) | HDAC1HDAC11HDAC8HDAC6MAPT | |
| SCHEMBL1058355 | 0.85 | HDAC1 (0.66) | HDAC1HDAC11HDAC8HDAC6POLB | |
| SCHEMBL16668055 | 0.84 | MEN1 (0.62) | HDAC1HDAC11HDAC8HDAC6MAPT | |
| SCHEMBL1002975 | 0.81 | HDAC6 (0.67) | HDAC1HDAC8HDAC6 | |
| SCHEMBL11641243 | 0.81 | DRD2 (0.56) | HDAC1HDAC11HDAC8HDAC6 | |
| SCHEMBL5438238 | 0.80 | P2RX4 (0.66) | HDAC1HDAC8HDAC6 | |
| SCHEMBL10487857 | 0.77 | MAPT (0.64) | HDAC1HDAC11HDAC8HDAC6MAPT | |
| SCHEMBL7812028 | 0.76 | HDAC1 (0.49) | HDAC1HDAC6MAPTALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6774134-B2 | FOR THERAPY OF RESPIRATORY SYNCYTIAL VIRUS INFECTION | BRISTOL-MYERS SQUIBB COMPANY | 2004-08-10 | — | — | US | disclosed |
| US-6774134-B2 | FOR THERAPY OF RESPIRATORY SYNCYTIAL VIRUS INFECTION | BRISTOL-MYERS SQUIBB COMPANY | 2004-08-10 | — | — | US | disclosed |